Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping, as many prominent players such as Abbvie , Jannsen, Dermavant Sciences, UCB , Eli Lilly and Company, Boehringer Ingelheim, Pfizer , Arcutis Biotherapeutics, Amgen , Mylan , Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Medical Care Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline , Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd., Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals and many others are developing Psoriasis therapies.
Los Angeles, USA , March 02, 2021 (GLOBE NEWSWIRE) -- Psoriasis Pipeline Insight 2021 | Latest Advancements in Clinical Trials to Improve Treatment
Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping, as many prominent players such as Abbvie , Jannsen, Dermavant Sciences, UCB , Eli Lilly and Company, Boehringer Ingelheim, Pfizer , Arcutis Biotherapeutics, Amgen , Mylan , Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Medical Care Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline , Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd., Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals and many others are developing Psoriasis therapies.
DelveInsight’s “Psoriasis Pipeline Insight'' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscapes. It comprises Psoriasis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Psoriasis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Psoriasis pipeline products.
Some of the important features of the Psoriasis Pipeline Report
Request for sample pages @ Psoriasis Clinical Trial Insight
Psoriasis is a chronic, immune-mediated inflammatory skin disease, which is characterized by the presence of papules and plaques occurring mainly on the elbows, knees, scalp, and lower back but is not restricted to these areas.
There is no cure for Psoriasis; however, there are multiple effective treatment options; topical therapy is the standard of care for treatment.
S.No. | Drug | Company | Phase | Product format |
1 | MYL-1401A | Mylan | Registered | Biologic |
2 | Abrilada | Pfizer | Registered | Biologic |
3 | Roflumiast | Arcutis Biotherapeutics | Phase III | Topical |
4 | ABP-654 | Amgen | Phase III | Biologic |
5 | BMS-986165 | Bristol-Myers Squibb | Phase III | Oral |
6 | Piclidenoson | Can-Fite Biopharma | Phase III | Oral |
7 | SNA021 | Santalis Pharmaceuticals | Phase II | Topical |
8 | SNA 120 | Sienna Biopharmaceuticals | Phase II | Topical |
9 | UHE-105 | Therapeutics Inc. | Phase II | Topical |
10 | MP1032 | MetrioPharm | Phase II | Oral |
11 | SCD-044 | Sun Pharmaceutical Industries Limited | Phase II | Oral |
12 | PF-06826647 | Pfizer | Phase II | Oral |
13 | M1095 | Avillion LLP | Phase II | Intravenous |
14 | NP000888 | Galderma R&D | Phase II | Topical |
15 | LEO 29102 | LEO Pharma | Phase II | Topical |
16 | JNJ-38518168 | Janssen Research & Development, LLC | Phase II | Oral |
19 | TAB08 | Theramab LLC | Phase I/II | Intravenous |
20 | ESR-114 | Escalier Biosciences | Phase I/II | Topical |
21 | SCB-808 | Clover Biopharmaceuticals | Phase I | Subcutaneous |
22 | ABBV-157 | Abbvie | Phase I | Oral |
23 | AK111 | Akesobio Australia Pty Ltd | Phase I | Subcutaneous |
For further product profiles, request @ Psoriasis Pipeline Landscape
Scope of Psoriasis Pipeline Drug Insight
Key Questions regarding Current Psoriasis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
1 | Psoriasis Report Introduction |
2 | Psoriasis Overview |
3 | Psoriasis Current Treatment Patterns |
4 | Psoriasis Analytical Perspective |
5 | Psoriasis Pipeline Therapeutic Assessment |
6 | Psoriasis Late Stage Products (Phase III) |
7 | Psoriasis Mid Stage Products (Phase II) |
8 | Psoriasis Pre-clinical Products and Discovery Stage Products |
9 | Psoriasis Inactive Products |
10 | Psoriasis Dormant Products |
11 | Psoriasis Discontinued Products |
12 | Psoriasis Product Profiles |
13 | Psoriasis Key Companies |
14 | Psoriasis Key Products |
15 | Psoriasis Unmet Needs |
16 | Psoriasis Future Perspectives |
17 | Psoriasis Analyst Views |
18 | Appendix |
19 | Report Methodology |
20 | About DelveInsight |
Get customized pipeline report @ Psoriasis Drug Treatment
Related Reports
DelveInsight's Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Psoriasis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Psoriasis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's Chronic Plaque Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Mild To Moderate Plaque Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Moderate Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Plaque Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Psoriasis Vulgaris - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
CONTACT: Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com